Stem cell-mediated exon skipping of the dystrophin gene by the bystander effect

Current Gene Therapy

Volumn 15, Issue 6, 2015, Pages 563-571

  Meregalli, Mirella ^a   Farini, Andrea ^a   Sitzia, Clementina ^a   Beley, Cyriaque ^b   Razini, Paola ^a   Cassinelli, Letizia ^a   Colleoni, Federica ^a   Frattini, Paola ^a   Santo, Nadia ^a   Galbiati, Elisabetta ^c   Prosperi, Davide ^c   Tavelli, Alessandro ^a   Belicchi, Marzia ^a   Garcia, Luis ^b   Torrente, Yvan ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Bystander effect; Delivery of exon skipping machinery; Myogenic stem cells

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CD133 ANTIGEN; DYSTROPHIN; LENTIVIRUS VECTOR; MESSENGER RNA; NANOPARTICLE;

ARTICLE; BYSTANDER EFFECT; CELL CLONE; CLINICAL ARTICLE; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; DYSTROPHIN GENE; ELECTRON MICROSCOPY; EXON SKIPPING; EXOSOME; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MECHANICAL STRESS; MEMBRANE VESICLE; NESTED POLYMERASE CHAIN REACTION; OPEN READING FRAME; POLYMERASE CHAIN REACTION; PREMATURE MORTALITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; STEM CELL TRANSPLANTATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CYTOLOGY; EXON; GENE THERAPY; GENETICS; MOUSE; MUSCULAR DYSTROPHY, DUCHENNE; PATHOLOGY; PHYSIOLOGY; PROCEDURES; RNA SPLICING; SCID MOUSE; SKELETAL MUSCLE; STEM CELL;

ANIMALS; BYSTANDER EFFECT; CELLS, CULTURED; DYSTROPHIN; EXONS; GENETIC THERAPY; HUMANS; MICE; MICE, SCID; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDES, ANTISENSE; RNA SPLICING; STEM CELLS;

EID: 84947923771     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523215666150929111400     Document Type: Article

References (41)

1. Emery AE. The muscular dystrophies. Lancet 2002; 359(9307): 687-95.
2. Koenig M, Beggs AH, Moyer M, et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 1989; 45(4): 498-506.
3. Monaco AP, Bertelson CJ, Liechti-Gallati S, et al. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988; 2(1): 90-5.
4. Pramono ZA, Takeshima Y, Alimsardjono H, et al. Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. Biochem Biophys Res Commun 1996; 226(2): 445-9.
5. Mann CJ, Honeyman K, Cheng AJ, et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA 2001; 98(1): 42-7.
6. Lu QL, Rabinowitz A, Chen YC, et al. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in bodywide skeletal muscles. Proc Natl Acad Sci USA 2005; 102(1): 198- 203.
7. Yokota T, Hoffman E, Takeda S. Antisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy. Methods Mol Biol 2011; 709: 299-312.
8. Yokota T, Lu QL, Partridge T, et al. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 2009; 65(6): 667-76.
9. Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011; 378(9791): 595-605.
10. Goemans NM, Tulinius M, van den Akker JT, et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011; 364(16): 1513-22.
11. Heemskerk H, de Winter CL, van Ommen GJ, et al. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy. Ann NY Acad Sci 2009; 1175: 71-9.
12. van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007; 357(26): 2677-86.
13. Goyenvalle A, Davies KE. Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy. Skelet Muscle 2011; 1(1): 8.
14. Wiklander OP, Nordin JZ, O'Loughlin A, et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J Extracell Vesicles 2015; 4: 26316.
15. Aliotta JM, Lee D, Puente N, et al. Progenitor/stem cell fate determination: interactive dynamics of cell cycle and microvesicles. Stem Cells Dev 2012; 21(10): 1627-38.
16. Farini A, Meregalli M, Belicchi M, et al. T and B lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid/mdx mouse. J Pathol 2007; 213(2): 229-38.
17. Torrente Y, Belicchi M, Sampaolesi M, et al. Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle. J Clin Invest 2004; 114(2): 182-95.
18. Meregalli M, Navarro C, Sitzia C, et al. Full-length dysferlin expression driven by engineered human dystrophic blood derived CD133+ stem cells. FEBS J 2013; 280(23): 6045-60.
19. Goyenvalle A, Vulin A, Fougerousse F, et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 2004; 306(5702): 1796-9.
20. Naldini L, Blomer U, Gage FH, et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93(21): 11382-8.
21. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272(5259): 263-7.
22. Benchaouir R, Meregalli M, Farini A, et al. Restoration of human dystrophin following transplantation of exon-skipping-engineered DMD patient stem cells into dystrophic mice. Cell Stem Cell 2007; 1(6): 646-57.
23. Franquesa M, Hoogduijn MJ, Ripoll E, et al. Update on controls for isolation and quantification methodology of extracellular vesicles derived from adipose tissue mesenchymal stem cells. Front Immunol 2014; 5: 525.
24. Farini A, Sitzia C, Navarro C, et al. Absence of T and B lymphocytes modulates dystrophic features in dysferlin deficient animal model. Exp Cell Res 2012; 318(10): 1160-74.
25. Bottinelli R, Canepari M, Pellegrino MA, et al. Force-velocity properties of human skeletal muscle fibres: myosin heavy chain isoform and temperature dependence. J Physiol 1996; 495(Pt 2): 573-86.
26. Xu X, Shuen WH, Chen C, et al. Swap70b is required for convergent and extension cell movement during zebrafish gastrulation linking Wnt11 signalling and RhoA effector function. Dev Biol 2014; 386(1): 191-203.
27. Bauer N, Wilsch-Brauninger M, Karbanova J, et al. Haematopoietic stem cell differentiation promotes the release of prominin- 1/CD133-containing membrane vesicles--a role of the endocyticexocytic pathway. EMBO Mol Med 2011; 3(7): 398-409.
28. Wu B, Benrashid E, Lu P, et al. Targeted skipping of human dystrophin exons in transgenic mouse model systemically for antisense drug development. PLoS One 2011; 6(5): e19906.
29. Yang L, Niu H, Gao X, et al. Effective exon skipping and dystrophin restoration by 2'-o-methoxyethyl antisense oligonucleotide in dystrophin-deficient mice. PLoS One 2013; 8(4): e61584.
30. Cerletti M, Jurga S, Witczak CA, et al. Highly efficient, functional engraftment of skeletal muscle stem cells in dystrophic muscles. Cell 2008; 134(1): 37-47.
31. Rouger K, Larcher T, Dubreil L, et al. Systemic delivery of allogenic muscle stem cells induces long-term muscle repair and clinical efficacy in duchenne muscular dystrophy dogs. Am J Pathol 2011; 179(5): 2501-18.
32. Tran T, Andersen R, Sherman SP, et al. Insights into skeletal muscle development and applications in regenerative medicine. Int Rev Cell Mol Biol 2013; 300: 51-83.
33. Torrente Y, Belicchi M, Marchesi C, et al. Autologous transplantation of muscle-derived CD133+ stem cells in Duchenne muscle patients. Cell Transplant 2007; 16(6): 563-77.
34. Negroni E, Riederer I, Chaouch S, et al. In vivo myogenic potential of human CD133+ muscle-derived stem cells: a quantitative study. Mol Ther 2009; 17(10): 1771-8.
35. Forterre A, Jalabert A, Berger E, et al. Proteomic analysis of C2C12 myoblast and myotube exosome-like vesicles: a new paradigm for myoblast-myotube cross talk? PLoS One 2014; 9(1): e84153.
36. Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteomics 2010; 73(10): 1907-20.
37. Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9(6): 654-9.
38. Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, et al. Tumourderived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother 2006; 55(7): 808-18.
39. Ratajczak J, Miekus K, Kucia M, et al. Embryonic stem cellderived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 2006; 20(5): 847-56.
40. Guescini M, Guidolin D, Vallorani L, et al. C2C12 myoblasts release micro-vesicles containing mtDNA and proteins involved in signal transduction. Exp Cell Res 2010; 316(12): 1977-84.
41. Le Bihan MC, Bigot A, Jensen SS, et al. In-depth analysis of the secretome identifies three major independent secretory pathways in differentiating human myoblasts. J Proteomics 2012; 77: 344-56.